David P. Kelsen

20.9k total citations · 3 hit papers
82 papers, 6.0k citations indexed

About

David P. Kelsen is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, David P. Kelsen has authored 82 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Surgery, 59 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in David P. Kelsen's work include Esophageal Cancer Research and Treatment (56 papers), Gastric Cancer Management and Outcomes (48 papers) and Esophageal and GI Pathology (20 papers). David P. Kelsen is often cited by papers focused on Esophageal Cancer Research and Treatment (56 papers), Gastric Cancer Management and Outcomes (48 papers) and Esophageal and GI Pathology (20 papers). David P. Kelsen collaborates with scholars based in United States, Canada and Germany. David P. Kelsen's co-authors include Bruce D. Minsky, Robert J. Ginsberg, Thomas F. Pajak, David H. Ilson, Jaffer A. Ajani, Norman Estes, Daniel G. Haller, Walter Kocha, Jack A. Roth and Joanne Mortimer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

David P. Kelsen

81 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer

1998 997 citations David P. Kelsen, Robert J. Ginsberg et al. profile →
INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy

2002 799 citations Bruce D. Minsky, Thomas F. Pajak et al. Journal of Clinical Oncology profile →
Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting

1981 555 citations Richard J. Gralla, Loretta M. Itri et al. profile →

Peers

Countries citing papers authored by David P. Kelsen

Since Specialization

Citations

This map shows the geographic impact of David P. Kelsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Kelsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Kelsen more than expected).

Fields of papers citing papers by David P. Kelsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David P. Kelsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Kelsen. The network helps show where David P. Kelsen may publish in the future.

Co-authorship network of co-authors of David P. Kelsen

This figure shows the co-authorship network connecting the top 25 collaborators of David P. Kelsen. A scholar is included among the top collaborators of David P. Kelsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David P. Kelsen. David P. Kelsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Positron-Emission Tomography Scan–Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders 2018 ·Journal of Thoracic Oncology ·Megan Greally, Joanne F. Chou, Daniela Molena, Valerie W. Rusch, Manjit S. Bains, Bernard J. Park, Abraham J. Wu, Karyn A. Goodman, David P. Kelsen, Yelena Y. Janjigian, David H. Ilson, Geoffrey Y. Ku	12
2	Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs) 2017 ·European Journal of Surgical Oncology ·Ulrich Ronellenfitsch, Matthias Schwarzbach, Ralf‐Dieter Hofheinz, P. Kienle, Kai Nowak, Meinhard Kieser, Tracy Slanger, Bryan Burmeister, David P. Kelsen, Donna Niedzwiecki, Christoph Schuhmacher, Susan G. Urba, (unknown), T. N. Walsh, Marc Ychou, Katrin Jensen	10
3	Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals 2016 ·Diseases of the Esophagus ·Thomas W. Rice, Hemant Ishwaran, David P. Kelsen, Wayne L. Hofstetter, Carolyn Apperson-Hansen, Eugene H. Blackstone	72
4	Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals 2016 ·Diseases of the Esophagus ·Thomas W. Rice, Hemant Ishwaran, Wayne L. Hofstetter, David P. Kelsen, Carolyn Apperson-Hansen, Eugene H. Blackstone	219
5	Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals 2016 ·Diseases of the Esophagus ·Thomas W. Rice, Hemant Ishwaran, Eugene H. Blackstone, Wayne L. Hofstetter, David P. Kelsen, Carolyn Apperson-Hansen	94
6	A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results 2002 ·Journal of Thoracic and Cardiovascular Surgery ·Manjit S. Bains, Alexander Stojadinovic, Bruce D. Minsky, Valerie W. Rusch, Alan D. Turnbull, Robert J. Korst, Robert J. Ginsberg, David P. Kelsen, David H. Ilson	56
7	INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy breakdown → 2002 ·Journal of Clinical Oncology ·Bruce D. Minsky, Thomas F. Pajak, Robert J. Ginsberg, Thomas M. Pisansky, James A. Martenson, Ritsuko Komaki, Gordon Okawara, Seth A. Rosenthal, David P. Kelsen	799
8	Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis 2000 ·Cancer Chemotherapy and Pharmacology ·Chung-Tsen Hsueh, Chang-Fang Chiu, David P. Kelsen, Gary K. Schwartz	51
9	Phase II clinical trial of 13-cis-retinoic acid and interferon-?-2a in patients with advanced esophageal carcinoma 1999 ·Cancer ·Peter C. Enzinger, David H. Ilson, Leonard B. Saltz, L. Martin, David P. Kelsen	12
10	MULTIMODALITY THERAPY FOR ADENOCARCINOMA OF THE ESOPHAGUS 1997 ·Gastroenterology Clinics of North America ·David P. Kelsen	13
11	Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer 1997 ·Diseases of the Colon & Rectum ·Alison Grann, Bruce D. Minsky, Alfred M. Cohen, Leonard B. Saltz, José G. Guillem, Philip B. Paty, David P. Kelsen, Nancy Kemeny, David H. Ilson, (unknown)	195
12	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma 1995 ·Cancer ·David H. Ilson, (unknown), Leonard B. Saltz, Robert T. Heelan, Ying Huang, Roger Keresztes, David P. Kelsen	26
13	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer 1994 ·Cancer ·(unknown), Alfred M. Cohen, Warren E. Enker, David P. Kelsen, Nancy Kemeny, David H. Ilson, José G. Guillem, Leonard B. Saltz, Joanne Frankel, (unknown)	112
14	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer 1993 ·Cancer ·Bruce D. Minsky, Joanne Frankel, Alfred M. Cohen, Warren E. Enker, Nancy E. Kemeny, David P. Kelsen, Leonard B. Saltz	90
15	Granulocyte Colony-Stimulating Factor: Effective in Ameliorating Fluorouracil Based Myelosuppression? 1993 ·JNCI Journal of the National Cancer Institute ·Karen L. Christman, Leonard B. Saltz, Gary K. Schwartz, Claudia Friedrich, David P. Kelsen	5
16	Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. 1992 ·Journal of Clinical Oncology ·Valerie W. Rusch, Donna Niedzwiecki, Yunxia Tao, C Menendez-Botet, Ann M. Dnistrian, David P. Kelsen, Leonard B. Saltz, Maurie Markman	89
17	Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. 1992 ·Journal of Clinical Oncology ·David P. Kelsen, David Lovett, Jason Wong, Leonard B. Saltz, Martin Buckley, P Murray, R T Heelan, Charles J. Lightdale	39
18	Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer. 1988 ·Journal of Clinical Oncology ·Bonnie Reichman, Maurie Markman, T. Hakes, Nancy E. Kemeny, David P. Kelsen, William J. Hoskins, Stephen C. Rubin, John L. Lewis	9
19	Neoadjuvant chemotherapy and surgery of cancer of the esophagus 1986 ·Seminars in Surgical Oncology ·David P. Kelsen, Basil S. Hilaris, Nael Martini	19
20	VP-16-213: A phase II study of non-small cell lung cancer (NSCLC) 1981 ·Proceedings of the American Association for Cancer Research ·Loretta M. Itri, Richard J. Gralla, David P. Kelsen	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact